Canada markets closed

Xenetic Biosciences, Inc. (XBIO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
4.0899+0.3199 (+8.49%)
At close: 04:00PM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) 6.30M
Enterprise Value -2.68M
Trailing P/E 2.01
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)2.46
Price/Book (mrq)0.64
Enterprise Value/Revenue -1.06
Enterprise Value/EBITDA 0.59

Trading Information

Stock Price History

Beta (5Y Monthly) 2.67
52-Week Change 3-4.88%
S&P500 52-Week Change 322.36%
52 Week High 35.9700
52 Week Low 32.5500
50-Day Moving Average 34.0973
200-Day Moving Average 33.8879

Share Statistics

Avg Vol (3 month) 35.69k
Avg Vol (10 day) 33.6k
Shares Outstanding 51.54M
Implied Shares Outstanding 61.54M
Float 81.25M
% Held by Insiders 119.05%
% Held by Institutions 11.10%
Shares Short (Apr 15, 2024) 42.8k
Short Ratio (Apr 15, 2024) 40.36
Short % of Float (Apr 15, 2024) 40.19%
Short % of Shares Outstanding (Apr 15, 2024) 40.18%
Shares Short (prior month Mar 15, 2024) 42.21k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Jun 25, 2019
Ex-Dividend Date 4N/A
Last Split Factor 21:10
Last Split Date 3May 15, 2023

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin -162.78%
Operating Margin (ttm)-186.87%

Management Effectiveness

Return on Assets (ttm)-22.29%
Return on Equity (ttm)-35.27%

Income Statement

Revenue (ttm)2.54M
Revenue Per Share (ttm)1.66
Quarterly Revenue Growth (yoy)38.00%
Gross Profit (ttm)N/A
EBITDA N/A
Net Income Avi to Common (ttm)-4.13M
Diluted EPS (ttm)-2.7100
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)8.98M
Total Cash Per Share (mrq)5.83
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)11.84
Book Value Per Share (mrq)6.36

Cash Flow Statement

Operating Cash Flow (ttm)-4.11M
Levered Free Cash Flow (ttm)-2.85M